COMMUNIQUÉS West-GlobeNewswire

Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update
06/08/2026
Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update Strategic partnering remains a key priority, with multiple strategic discussions progressing, including advanced term sheet [...]
IBA : Publication des résultats du premier semestre 2026 et conférence web
06/08/2026
La conférence sur les résultats du premier semestre 2026 aura lieu le jeudi 27 août 2026 à 15h00, heure de Bruxelles Louvain-la-Neuve, Belgique, le 06 août 2026, 7h00 - IBA (Ion Beam Applications S.A le leader mondial [...]
IBA Notice of Half Year 2026 Results and Conference Call
06/08/2026
HY26 results webcast to take place on Thursday, 27 August 2026 at 3 p.m. CEST Louvain-la-Neuve, Belgium, 6 August 2026, 7 a.m. - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator [...]
Actimed Therapeutics Reacquires Global Rights to S-oxprenolol, Broadening Pipeline Opportunity
06/08/2026
London, UK – 6 th August 2026. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting [...]
ARCPOINT ANNOUNCES FAILURE-TO-FILE CEASE TRADE ORDER
06/08/2026
GREENVILLE, South Carolina, Aug. 05, 2026 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “ Company ” or “ ARCpoint ”) announces that the British Columbia Securities Commission (the “ BCSC ”), as the Company’s [...]
Braveheart Bio Announces Pricing of Upsized Initial Public Offering
06/08/2026
SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other [...]
UPDATE - LifeMD Reports Second Quarter 2026 Results
06/08/2026
UPDATE this press release has been updated to remove a duplicate table. Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of [...]
CellFiber and Tidewave Bio Enter Collaboration to Evaluate Scalable 3D Manufacturing for Next-Generation Solid Tumor Immunotherapy
06/08/2026
Partnership pairs CellFiber’s proprietary hollow-fiber encapsulation platform with Tidewave Bio’s universal, off-the-shelf cell immunotherapy program in a proof-of-concept process evaluation TOKYO and LOS ANGELES, Aug. [...]
Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
06/08/2026
IRVINE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Thursday, August 6, 2026 to report its [...]
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals
06/08/2026
NANJING, China, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that its Phase II clinical study evaluating Opamtistomig (LBL-024 [...]
Editas Medicine Announces Second Quarter 2026 Results and Business Updates
05/08/2026
EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins, including LDL-C, Lp(a) [...]
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
05/08/2026
Presented positive Phase 2 results for silevertinib in frontline patients with non-classical EGFRm NSCLC at the 2026 ASCO Annual Meeting, including that no patients developed de novo brain metastases and that patients [...]
Carlsmed® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance
05/08/2026
Second quarter 2026 revenue of $18.9 million, representing 57% growth year-over-year Full year 2026 revenue guidance raised to $74 million to $78 million CARLSBAD, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc [...]
Biodesix Announces Second Quarter 2026 Results and Highlights
05/08/2026
Delivered $26.9 million in revenue, representing 34% growth in Q2 2026; Achieved 82% gross margin in Q2 2026; Maintained FY 2026 Revenue Guidance of $108-114 million, mid-point reflects 25% growth; Conference Call and [...]
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05/08/2026
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1, 2026, the Company [...]
Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
05/08/2026
U.S. FDA accepted daraxonrasib New Drug Application for review for previously treated metastatic pancreatic cancer following unprecedented Phase 3 RASolute 302 results Rapidly implemented U.S. Expanded Access Program [...]
Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems
05/08/2026
MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, [...]
Mangoceuticals’ Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development
05/08/2026
The MOU supports exploration of a nuclear test reactor site at the Utah San Rafael Energy Lab and engagement with the U.S. Department of Energy and Nuclear Regulatory Commission to advance the Morpheus microreactor [...]
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05/08/2026
CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, [...]

Pages